enVVeno Medical Corporation (NVNO)
NASDAQ: NVNO · Real-Time Price · USD
3.830
+0.350 (10.06%)
At close: Jun 6, 2025, 4:00 PM
3.831
+0.001 (0.04%)
After-hours: Jun 6, 2025, 7:51 PM EDT
enVVeno Medical Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
37
Market Cap
67.16M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
NVNO News
- 1 day ago - Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting - Accesswire
- 19 days ago - enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer - Accesswire
- 25 days ago - Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery - Accesswire
- 5 weeks ago - enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24 - Accesswire
- 6 weeks ago - VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium - Accesswire
- 7 weeks ago - enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment - Accesswire
- 2 months ago - The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium - Accesswire
- 3 months ago - enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25 - Accesswire